Recent deals and regulatory activities show drug companies' renewed interest in the women's health space. We look at which health issues they’re targeting, from endometriosis to HPV-related diseases.
The global women’s health market is projected to be worth over $51B by 2025, and drug companies may play a crucial part in getting it there.
But discovering blockbuster drugs hasn’t been an easy process.
Drug development companies with women’s health-specific portfolios have struggled to gain steady investor interest since 2015 and have faced setbacks with getting new treatments approved.
But a recent spike in deals and regulatory activities suggests that might be changing.